Clinical Significance of Temporalis and Masseter Muscle Volumes in Glioblastoma
Clinical Neuroimaging · 2026-01 · 3 (1)
DOI: 10.1002/neo2.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuroimaging, online erschienen am 19.05.2026. Verfasst von Preston Carey und 9 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Purpose Glioblastoma (GBM) is a primary CNS neoplasm with a dismal prognosis. Sarcopenia is an indicator of poor overall survival (OS) in a variety of cancers. Temporalis muscle thickness (TMT) and masseter muscle thicknesses (MMT) have been studied as surrogate markers for sarcopenia, while muscle volume has not. Our objective was to determine the utility of temporalis muscle volume (TMV) and masseter muscle volume (MMV) as a prognostic indicator in GBM patients.
Methods
This retrospective cohort study included adult patients with a primary IDHwt GBM diagnosis between 2008 and 2020, and Karnofsky Performance Scale (KPS) ≥ 60. TMT, MMT, TMV, and MMV were measured on CT Brain closest to date of diagnosis using Varian Eclipse v18.0. Cox proportional hazards regression was used to assess the association of TMT, MMT, TMV, and MMV with OS.
Results
99 patients were included. Median age was 61 years, most (71%) were male, and the mean BMI was 28.9 kg/m 2 . TMT and MMT were moderately correlated with TMV and MMV. None of our muscle indices demonstrated significant association with OS (adjusted p ‐value = 0.522 for TMT, 0.066 for TMV, 0.371 for MMT, and 0.597 for MMV). MGMT methylation and extent of resection were associated with significantly improved OS ( p < 0.001 for both).
Conclusion
Neither temporalis nor masseter muscle thickness or volume demonstrated a significant association with OS in patients with GBM. Given the modest sample size and limited statistical power, a prognostic role for these sarcopenia‐related measures cannot be excluded and warrants further investigation.
Zitieren
APA
Carey, P., Tam, E., Kata, R., Rafi, R., Cappelli, L., Kantor, J., Daskalakis, C., Alnahhass, I., Andrews, D., & Shi, W. (2026). Clinical Significance of Temporalis and Masseter Muscle Volumes in Glioblastoma. Clinical Neuroimaging, 3(1). https://doi.org/10.1002/neo2.70069
Vancouver
Carey P, Tam E, Kata R, Rafi R, Cappelli L, Kantor J, et al. Clinical Significance of Temporalis and Masseter Muscle Volumes in Glioblastoma. Clinical Neuroimaging. 2026;3(1). doi:10.1002/neo2.70069
BibTeX
@article{Carey2026,
author = {Carey, Preston and Tam, Emma and Kata, Rithvik and Rafi, Rabiul and Cappelli, Louis and Kantor, Jenna and Daskalakis, Constantine and Alnahhass, Iyad and Andrews, David and Shi, Wenyin},
title = {Clinical Significance of Temporalis and Masseter Muscle Volumes in Glioblastoma},
journal = {Clinical Neuroimaging},
year = {2026},
volume = {3},
number = {1},
doi = {10.1002/neo2.70069}
}
EUVIMED